CGEM NASDAQ
Cullinan Therapeutics, Inc.
1W: -12.2%
1M: -2.3%
3M: +14.0%
YTD: +40.1%
1Y: +89.1%
3Y: +45.3%
5Y: -53.4%
$14.52
+0.35 (+2.44%)
Weekly Expected Move ±10.4%
$12
$14
$16
$17
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$871.2M
52W Range5.68-16.74
Volume1,176,938
Avg Volume861,086
Beta-0.09
Dividend—
Analyst Ratings
Company Info
CEONadim Ahmed
Employees111
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2021-01-08
Websitecullinantherapeutics.com
One Main Street
Cambridge, MA 02142
US
Cambridge, MA 02142
US
617 410 4650
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Latest News
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics GAAP EPS of -$0.75
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-05-05 |
| Michaelson Jennifer | S-Sale | 7,800 | $14.60 | 2026-05-05 |
| Michaelson Jennifer | S-Sale | 200 | $15.58 | 2026-05-05 |
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-05-05 |
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-03-05 |